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Objective: Tumors down-regulate major histocompatibility complex class I expres-
sion, escaping recognition by the cellular immune response. We hypothesized that
augmentation of tumor cell class I expression by interferon-gamma would enhance
the cellular antitumor immune response and cure rate of an active immunotherapy
strategy.
Methods: B16.F10 tumor cells were exposed to interferon-gamma in culture, and
class I expression was quantified using flow cytometry. Syngeneic mice bearing
established tumors were injected with interferon-gamma (5000 U, intraperitoneal),
and class I expression was assessed using immunohistochemistry. Tumor-specific
cytotoxic T lymphocytes were induced in mice by an intratumoral injection of
AdCD40L (5  1010 particles), an adenovirus gene transfer vector-based immuno-
therapy strategy previously demonstrated to augment cellular antitumor immunity.
A conjugate-formation assay and the enzyme-linked immunospot assay were used to
evaluate the binding and activation of cytotoxic T lymphocytes, respectively.
Interferon-gamma was administered to tumor-bearing mice concomitantly with
intratumoral AdCD40L. End points measured included the frequencies of cytotoxic
T lymphocytes using the enzyme-linked immunospot assay, tumor size, and mouse
survival. The role of class I expression was further evaluated by monoclonal
antibody blockade in both in vitro and in vivo experiments.
Results: B16.F10 cells exposed to interferon-gamma expressed significantly more
class I, both in vitro and in vivo, and were able to bind to and activate cytotoxic T
lymphocytes more efficiently than untreated cells. Cytotoxic T-lymphocyte frequen-
cies, tumor regression, and the cure rate induced by AdCD40L were augmented by
the addition of a single dose of interferon-gamma in tumor-bearing mice. These in
vitro and in vivo effects of interferon-gamma were attenuated by class I monoclonal
antibody blockade.
Conclusions: Up-regulation of class I expression using interferon-gamma enhances
the cellular antitumor immune response and cure rate of AdCD40L, an active
immunotherapy strategy. This approach may be useful for human tumors that lack
class I expression.
The major histocompatibility complex (MHC) represents a collectionof genes encoding proteins that are integral in distinguishing be-tween self and nonself by the immune system.1-3 Class I MHCmolecules are glycoproteins expressed ubiquitously by most nucle-ated cells and have been shown to be necessary for the presentationof antigens manufactured by these cells to naive CD8 T lympho-
cytes.1-3 As such, class I molecules are thought to play a vital role in cell-mediated
immunity against virally infected cells as well as tumors.3 One mechanism by which
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tumor cells are thought to escape the antitumor immune
response is by attenuating their expression of MHC class I
molecules. For example, class I is only inconsistently ex-
pressed by human lung cancer cells in vitro and in vivo.4-8
Many agents, including some cytokines and chemother-
apeutics, have been shown to enhance MHC class I expres-
sion by tumor cells.8-10 One of the most well-characterized
modulators in this regard is interferon-gamma (IFN),
which has been shown to enhance class I expression in
multiple human lung cancer cell lines.8,10 Despite this, a
paucity of data exists concerning the modulation of class I
molecule expression by IFN in established tumors in vivo.
In our laboratory, we have developed active antitumor im-
munotherapy strategies that are dependent on the generation
of tumor-specific, cellular immunity.11,12 One of these strat-
egies has involved the transduction of established murine
tumors with an adenovirus (Ad) gene transfer vector con-
taining the gene for CD40 ligand (AdCD40L).11 However,
these strategies have been clearly less effective in murine
tumors that express low levels of MHC class I.11,12 Given
that IFN enhances the expression of class I by tumor cells
in vitro,8,10 we hypothesized that administration of IFN to
mice bearing established tumors would up-regulate MHC
class I expression by the tumors and, subsequently, enhance
tumor-specific cellular immunity induced by AdCD40L. In
this regard, the data show that (1) exposure of B16.F10
tumor cells to IFN augments MHC class I expression in
vitro and in vivo and enhances tumor cell binding to tumor-
specific cytotoxic T lymphocytes (CTLs); (2) treatment of
tumor-bearing mice with a single dose of IFN results in
more efficient generation of tumor-specific CTLs by an
active immunotherapy strategy (AdCD40L); (3) exposure of
B16.F10 tumor cells to IFN enhances tumor-specific CTL
activation in coculture; (4) a single dose of IFN adminis-
tered to tumor-bearing mice augments the antitumor activity
and cure rate of an established immunotherapy strategy
(AdCD40L); and (5) these synergistic effects of IFN are
attenuated by the administration of an anti-MHC class I
monoclonal antibody (MAb).
Materials and Methods
Mice
Female wild-type C57BL/6 (H-2b) mice (6-8 weeks old) were
obtained from Jackson Laboratories (Bar Harbor, Me). The mice
were housed under specific pathogen-free conditions and treated
according to the National Institutes of Health guidelines. All
animal procedures were approved by the Institutional Animal Care
and Use Committee.
Cell Culture
B16.F10 (H-2b) and Lewis Lung Carcinoma (LLC; H-2b) are
syngeneic to C57BL/6 mice. The cell lines were obtained from
American Type Culture Collection (ATCC, Manassas, Va; catalog
no. CRL 6475) and maintained in complete Dulbecco’s modified
Eagle’s medium (DMEM; 10% fetal bovine serum, 100 g/mL
streptomycin, and 100 U/mL penicillin) at 5% CO2 and 37°C.
Adenovirus Vectors
All gene transfer vectors used in this study are replication-defi-
cient, E1-, E3-vectors based on the adenovirus serotype 5 (Ad5)
genome. AdCD40L contains an expression cassette with the mu-
rine CD40L cDNA under the control of the cytomegalovirus
early-immediate promoter/enhancer.11 AdNull, a control vector, is
similar to AdCD40L but contains an empty expression cassette.13
Adenovirus vectors were propagated in human embryonic kidney
cells (293 cells; ATCC) and purified through 2 cesium chloride
gradient ultracentrifugations as previously described.14,15 The vi-
ral particle concentration was determined by ultraviolet absor-
bance at 260 nm.16
Quantification of MHC Class I Expression in Vitro
To determine whether IFN up-regulates the expression of class I
by B16.F10 cells in vitro, 50% confluent B16.F10 cells were
exposed to 500 U/mL of recombinant murine IFN (rmIFN;
Roche Diagnostics, Mannheim, Germany) for 48 hours in com-
plete DMEM at 37°C. The cells were harvested, washed 3 times
with phosphate-buffered saline (PBS), and stained with either
fluorescein isothiocyanate (FITC)-conjugated mouse anti-mouse
H-2Kb MAb or FITC-mouse immunoglobulin G (IgG)2 isotype
control antibody (Pharmingen, San Diego, Calif). The cells were
then subjected to flow cytometric analysis (FACStar, Becton Dick-
inson, San Jose, Calif) to determine H-2Kb MHC class I expres-
sion.
Modulation of MHC Class I Expression in Vivo
To assess the ability of IFN to enhance MHC class I expression
by established tumors in vivo, 5  105 B16.F10 cells were
injected subcutaneously in the right flanks of wild-type
C57BL/6 mice. When the tumors were approximately 45 to 50
mm2 (day 8), a single subtherapeutic dose (5000 U) of rmIFN
was administered into the peritoneal cavity (IP). The animals
were killed and the tumors harvested 24 or 48 hours after
rmIFN injection. Untreated tumor-bearing mice served as neg-
ative controls. The tumors were resected from the right flank,
embedded in Optimal Cutting Temperature compound (Sakura
Finetek, Torrance, Calif), snap-frozen in a 2-methylbutane/dry
ice bath, and prepared as 10-m frozen sections. The tumor
sections were blocked with 5% goat serum (Sigma Chemical
Co, St Louis, Mo) for 20 minutes, washed with PBS, and
incubated with a biotin-conjugated mouse anti-mouse H-2Kb
MAb (Pharmingen) for 2 hours. The slides were then washed
with PBS and incubated with avidin-horseradish peroxidase
solution (Pharmingen) for 30 minutes. After further washing
with PBS, the tumor sections were exposed to 3,3'-diaminoben-
zidine chromagen substrate (Pharmingen) for 10 minutes,
washed with PBS, and counterstained with hematoxylin. Fol-
lowing 3 washes with deionized water, the tumor sections were
rehydrated with 95% ethanol and mounted for light microscopy.
Generation and Purification of Tumor-Specific
Cytotoxic T Lymphocytes
To generate activated tumor-specific CD8 CTLs, 5  105
B16.F10 cells were injected into the right flanks of C57BL/6 mice.
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When the tumors reached 45 to 50 mm2, AdCD40L (5  1010
particle units in 100 L PBS) was injected intratumorally. Seven
days after AdCD40L administration, the mice were killed and their
spleens were harvested. The spleens were minced with a razor and
passed through a 100-m nylon mesh filter. The resulting spleno-
cyte suspensions were treated with ACK Lysing Buffer (Biosource
International, Camarillo, Calif) to lyse red blood cells and washed
with PBS. The Spinsep murine cell enrichment procedure (Stem
Cell Technologies, Vancouver, BC, Canada) was then performed
to purify CD8 T lymphocytes according to the manufacturer’s
instructions. Flow cytometic analysis indicated that 90% of the
purified splenocytes were CD8 T lymphocytes (data not shown).
Cytotoxic T-Lymphocyte Binding Assay
To assess the ability of CTLs to bind to target cells, a conjugate-
formation binding assay was performed as described by Nakamura
and colleagues17 and Noguchi and colleagues.18 B16.F10 cells
were cultured in either complete DMEM or complete DMEM with
the addition of 500 U/mL of rmIFN for 48 hours. The cells were
collected using trypsin-ethylenediaminetetraacetic acid and
washed 3 times with PBS. The B16.F10 tumor cells were stained
with 1 g/mL of hydroethidine (Molecular Probes, Junction City,
Ore) for 1 hour at 37°C. The purified CD8 T lymphocytes from
AdCD40L-treated mice were stained with 1 g/mL of sulfofluo-
resceindiacetate (Molecular Probes) for 1 hour at 37°C. The
stained CD8 T lymphocytes were then cocultured with either
rmIFN-exposed B16.F10 cells or untreated B16.F10 cells at a 1:1
ratio (8  104 cells each) for 15 minutes at 37°C. Purified mouse
anti-mouse H-2Kb MAb (4 g; Pharmingen) was added to se-
lected wells to assess the role of MHC class I in CTL binding.
Binding of CD8 T lymphocytes and B16.F10 cells was then
quantified using 2-color flow cytometry (FACStar; Becton Dick-
inson). The percentage of bound CD8 cells was calculated as
follows: Binding (%)  (no. of green-red double positive counts)/
(total no. of green positive counts)  100.
IFN Enzyme-Linked Immunospot Assay
To quantify the frequencies of tumor-specific CTLs, the enzyme-
linked immunospot (ELISPOT) assay was employed. The ELIS-
POT assay is a sensitive and reproducible assay for the functional
and quantitative determination of the proportion of tumor-specific
CTLs19,20 and has become a standard method for the determination
of CTLs in immunotherapy clinical trials.20 Each spot observed in
the assay represents a single, tumor-specific, activated T lympho-
cyte, detected by its ability to secrete IFN.
Target cell preparation. Target cells consisted of B16.F10
cells exposed to rmIFN (500 U/mL; 48 hours), untreated B16.F10
cells, or the syngeneic negative control cell line, LLC. Prior to
their use in the ELISPOT assay, target cells were washed with PBS
and treated with 100 g/mL of mitomycin C (Sigma) at 37°C for
1 hour. The tumor cells were then washed in complete ELISPOT
medium (RPMI 1640 supplemented with 10% fetal bovine serum,
100 g/mL streptomycin, 100 U/mL penicillin, 10 mmol/L N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer, 1 mmol/L
L-glutamine, and 5  105 mol/L -mercaptoethanol) and resus-
pended at 106 cells/mL.
Effector cell preparation. Effector cells for use in the ELIS-
POT assay were generated using the in vivo tumor model previ-
ously described (see Generation and Purification of Tumor-Spe-
cific Cytotoxic T Lymphocytes). Four groups of effector cells were
prepared, which included total splenocytes from (1) AdCD40L-
treated mice, (2) AdCD40L-treated mice that also received a
concomitant IP injection of rmIFN (5000 U), (3) AdNull-treated
mice, and (4) PBS-treated mice. Unlike the preparation for the
binding assay, CD8 T cells were not purified from total spleno-
cytes for use in the ELISPOT assay, with the goal of preserving the
presence of antigen-presenting cells. The splenocytes were resus-
pended in complete ELISPOT medium at a concentration of 8 
106 cells/mL.
ELISPOT assay. Ninety-six–well multiscreen-IP membrane
plates (Millipore, Bedford, Mass) were coated with 100 L of a rat
anti-mouse IFN MAb (Mabtech, Cincinnati, Ohio) at a concen-
tration of 10 g/mL overnight at 4°C. The plates were blocked
with 150 L of complete ELISPOT medium and incubated for 2
hours at 37°C. The blocking buffer was decanted and 4  105
splenocytes/50 L of complete ELISPOT medium were added to
each well, followed by incubation for 2 hours at 37°C. Target cells
(5  104 cells/50 L of complete ELISPOT medium) were then
added to each well and the plates were incubated for 20 hours at
37°C. After incubation, the plates were washed with PBS and
0.05% Tween 20 (Sigma). A biotinylated anti-rat IgG antibody
(Mabtech) was diluted to 1 g/mL in PBS/0.5% bovine serum
albumin, and 100 L was added to each well. The plates were
incubated for 2 hours at 37°C and washed with PBS/0.05% Tween
20. After washing, 100 L of avidin-enzyme complex (Vector
Laboratories, Burlingame, Calif) was added to each well and
incubated for 1 hour at room temperature. The plates were then
washed and treated with 100 L of 3-amino-9-ethylcarbazole
substrate (Sigma) and incubated for 4 minutes at room tempera-
ture, followed by rinsing with water to stop the reaction. The plates
were then analyzed with the KS ELISPOT Automated Reader
System (Carl Zeiss, Chester, Va).
Evaluation of in Vivo MHC Class I Expression
Modulation on the Antitumor Properties of AdCD40L
B16.F10 tumor cells (5  105 cells in 100 L of PBS) were
injected into the right flanks of C57BL/6 mice. When the tumor
growth reached 45 to 50 mm2, treatment with PBS, AdNull, or
AdCD40L (5  1010 particles) was administered intratumorally in
100 L of PBS. Additional mice received a single dose of IP
rmIFN alone (5000 U), with AdNull, or with AdCD40L. The size
of the flank tumors was assessed every 2 to 3 days by measuring
the largest perpendicular diameters using microcalipers and were
recorded as an average tumor area (mm2). When the animals
appeared moribund or the tumor growth exceeded 15 mm in the
largest diameter, the mice were killed and this time point was
defined as date of death for survival analysis.
Evaluation of MHC Class I Blockade with MHC Class
I MAb in Vivo
To assess the role of MHC class I expression enhancement by
IFN in vivo, tumor-bearing mice receiving intratumoral
AdCD40L (5 1010 particles) and IP IFN (5000 U) were treated
with 3 successive intratumoral injections of mouse anti-mouse
H-2Kb MAb (20 g/100 L PBS; Sigma) on days 8 to 10 after
tumor injection. Untreated mice and mice treated with AdCD40L
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and IFN served as controls. The size of the flank tumors was
assessed every 2 days by measuring the largest perpendicular
diameters using microcalipers and were recorded as an average
tumor area (mm2). A subset of mice from each group were killed
7 days after AdCD40L and IFN injection and the spleens were
harvested. The frequencies of tumor-specific CTLs were then
evaluated using the ELISPOT assay as previously described.
Statistical Analysis
All data are reported as the mean  SEM unless otherwise spec-
ified. Statistical significance between means was determined using
the unpaired, 2-tailed Student t test. Survival evaluation was per-
formed using the Kaplan-Meier analysis (P values were deter-
mined by Breslow test for significance).
Results
Exposure of B16.F10 Cells to rmIFN Enhances MHC
Class I Expression in Vitro
The effect of rmIFN on the expression of MHC class I was
determined by incubating B16.F10 cells with 500 U/mL of
rmIFN for 48 hours. B16.F10 cells exposed to 500 U/mL
of rmIFN demonstrated significantly enhanced expression
of MHC class I molecules compared with naive B16.F10
cells (Figure 1). Of the B16.F10 cells treated with rmIFN,
95% expressed MHC class I while naive B16.F10 cells did
not show any detectable expression. B16.F10 cells exposed
to rmIFN and stained with an isotype-matched control
antibody did not demonstrate any detectable MHC class I
expression (data not shown).
Treatment of B16.F10 Tumor-Bearing Mice with a
Single Dose of rmIFN Enhances MHC Class I
Expression in Vivo
To determine if rmIFN would enhance expression of MHC
class I in established B16.F10 tumors in vivo, tumor-bear-
ing mice were injected with a single IP dose of rmIFN
(5000 U). The tumors from mice receiving rmIFN uni-
formly expressed the H-2Kb MHC class I antigen at both 24
and 48 hours following administration of the cytokine (Fig-
ure 2, A and B). B16.F10 tumors from untreated mice
expressed low levels of H-2Kb MHC class I (Figure 2, C).
There was also no detection of H-2Kb antigen in B16.F10
tumors that were stained with the isotype-matched control
antibody (not shown).
Exposure of B16.F10 Tumor Cells to rmIFN
Enhances Binding of CD8 T Lymphocytes in Vitro
The conjugate-formation assay was performed to establish
the effect of rmIFN on the ability of CD8 CTLs to bind
to tumor cells (a class I–mediated phenomenon). The CD8
CTLs were able to bind B16.F10 cells more effectively if
the tumor cells had been exposed to rmIFN (Figure 3, B
and D) compared with untreated tumor cells (Figure 3, A
and D; P .002). Furthermore, the addition of an MAb that
binds MHC class I to these reaction conditions clearly
inhibited the binding of CTLs to target cells (Figure 3, C
and D; P  .007, rmIFN-exposed cells incubated with
H-2Kb MHC class I MAb vs rmIFN-exposed cells alone).
Prior Exposure of Target Tumor Cells to rmIFN in
Culture Enhances Tumor-Specific Cytotoxic T-
Lymphocyte Activation in Vitro
Because the class I–mediated binding of CTLs (effector
cells) to tumor cells (target cells) results in activation of the
bound T cells,21-23 we sought to determine whether the
enhanced binding induced by rmIFN exposure between
these cells would augment CTL activation. To accomplish
this, splenocytes from B16.F10 tumor-bearing mice that
received intratumoral PBS, AdNull, or AdCD40L were
harvested and incubated in vitro with untreated B16.F10
cells, B16.F10 cells exposed to rmIFN, or LLC negative
control cells for 20 hours in anti-IFN MAb-coated 96-well
plates (ELISPOT assay). As an additional control, spleno-
cytes were incubated in complete ELISPOT medium with-
out tumor cells. When the effector cells (splenocytes) were
obtained from AdCD40L-treated mice, previous exposure
of the B16.F10 cells (target cells) to rmIFN resulted in
significantly greater frequencies of activated CTLs com-
pared with stimulation with B16.F10 cells that had not been
exposed to this cytokine (Figure 4, A; P  .01). As ex-
pected, minimal CTL activation was observed when spleno-
cytes were obtained from untreated tumor-bearing mice
(Figure 4, B), mice that received AdNull (Figure 4, C), or
Figure 1. Exposure of B16.F10 cells to rmIFN in vitro increases
H-2Kb MHC class I expression. B16.F10 cells were exposed to 500
U/mL of rmIFN for 48 hours, followed by staining with FITC-
labeled mouse anti-mouse H-2Kb MAb or an isotype-matched
control antibody, and subjected to flow cytometry; 0.42% of un-
treated B16.F10 cells bound the fluorescent label, compared with
95% of B16.F10 cells that had been exposed to rmIFN. The
experiment shown represents 1 of multiple performed.
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naive, tumor-free mice (Figure 4, D), regardless of the target
cell type.
The Addition of a Single Dose of rmIFN to an Active
Immunotherapy Strategy Enhances Cytotoxic T-
Lymphocyte Generation in the Tumor-Bearing Host
Because MHC class I expression plays an integral role in
the presentation of tumor antigens to naive T lymphocytes,
we sought to determine whether up-regulating MHC class I
expression by established tumors in vivo (using rmIFN)
would result in enhanced generation of tumor-specific CTLs
when combined with an active immunotherapy strategy. To
investigate this, B16.F10 tumor-bearing mice were either
treated with intratumoral AdCD40L or AdNull or left un-
treated. A similar experiment was simultaneously con-
ducted with the same groups, except that a single IP dose of
rmIFN was administered (5000 U). LLC cells served as
control target cells. The relative frequency of CTLs was
then assessed using the ELISPOT assay. Significantly
greater frequencies of activated tumor-specific CTLs were
obtained from the spleens of mice that had received both
AdCD40L and rmIFN when compared with AdCD40L
alone (Figure 5; P .000004) or any other treatment group.
In addition, minimal CTL generation was observed in any
group when LLC cells were used as targets (not shown).
The Addition of a Single Dose of rmIFN Enhances
the Antitumor Activity and Cure Rate of AdCD40L
To determine whether the addition of a single dose of
rmIFN would augment the antitumor properties of
AdCD40L in vivo, B16.F10 tumor-bearing mice were given
intratumoral AdCD40L as well as IP rmIFN (5000 U)
concomitantly. Additional groups of mice were treated with
intratumoral PBS, AdNull, AdNull with IP rmIFN, or IP
rmIFN alone. Tumor regression was more pronounced in
the mice receiving AdCD40L and rmIFN compared with
mice receiving AdCD40L alone (Figure 6, A; P  .004),
AdNull (P  .001), rmIFN alone (P  .0004), AdNull
with IFN (P  .001), or PBS (P  .0000004). In addition,
the cure rate observed with the combination of AdCD40L
and rmIFN was superior to that of any other group (Figure
6, B; P  .01 vs AdCD40L alone; P  .008 vs AdNull; P
 .0017 vs AdNull plus rmIFN; P  .0017 vs rmIFN
alone; P  .0018 vs PBS).
Blockade of MHC Class I in Vivo Attenuates the
Synergistic Effect of rmIFN on the Antitumor
Activity and CTL Generation Induced by AdCD40L
To dissect the role of enhanced MHC class I expression in
the synergistic effect of rmIFN on tumor regression and
CTL generation induced by AdCD40L, 3 successive intra-
tumoral injections of MHC class I MAb were administered.
The extent of tumor regression was significantly greater in
mice treated with AdCD40L and rmIFN compared with
mice receiving AdCD40L, IFN, and MHC class I MAb
(Figure 7, A; P  .007) or PBS alone (Figure 7, A; P 
.00001). This effect persisted for 6 days after the initial
intratumoral injection of MHC class I MAb, after which
time regression rates became similar between the 2 groups
receiving AdCD40L. In addition, the enhanced CTL gener-
ation afforded by rmIFN was significantly diminished in
the animals that received MAb blockade (Figure 7, B; P 
.016, AdCD40L, rmIFN vs AdCD40L, rmIFN plus anti-
class I MAb). Finally, minimal stimulation was observed in
any group when LLC cells were used as targets (not shown).
Figure 2. Intraperitoneal administration of rmIFN enhances the expression of H-2Kb MHC class I by established
B16.F10 flank tumors. B16.F10 tumors were established in C57BL/6 mice and rmIFN (5000 U) was injected as a
single IP dose. The tumors were resected 24 or 48 hours after rmIFN administration and evaluated using
immunohistochemistry. The dark brown surface membrane staining represents MHC class I expression. A,
Twenty-four hours after rmIFN treatment. B, Forty-eight hours after rmIFN treatment. C, Tumor from an untreated
mouse.
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Discussion
Lung cancer is responsible for more cancer deaths than any
other malignant tumor in the United States.24 Fewer than
15% of patients presenting with lung cancer will ever be
cured of their disease, with the vast majority of patients
succumbing to distant metastasis,24 implying that more ef-
fective systemic therapy is a priority for these patients.
Augmentation of antitumor immunity represents a treatment
strategy that has the potential to be both tumor-specific as
well as systemic in nature; however, reports describing its
use for patients with lung cancer have not conclusively
demonstrated efficacy.25 The antitumor immune response
has traditionally been divided into afferent (stimulatory) and
efferent (effector) limbs, with MHC class I molecules play-
ing an integral role in both limbs.1-3 One mechanism by
which tumor cells may evade the immune response is by
down-regulating the expression of MHC class I on their
surface, a process that could potentially interfere with both
CTL generation (afferent limb) as well as subsequent rec-
ognition and binding of CTLs to target tumor cells (effector
limb). This phenomenon is evident in human lung cancer
cell lines, where as many as 33% to 43% have lost MHC
class I expression.4,7,10 In our laboratory, which is focused
on the use of gene transfer to induce antitumor immunity,
we have observed that active immunotherapy strategies are
significantly less effective in murine tumor models that
express little or no MHC class I, exemplified by the meta-
static variant of the B16 melanoma, B16.F10.11,12 Given
this information, the purpose of the present study was to
determine whether MHC class I expression could be en-
Figure 3. Up-regulation of H-2Kb MHC class I expression enhances the binding of CD8 CTLs to B16.F10 tumor
cells in a conjugate-formation assay. Naive B16.F10 cells or rmIFN-exposed B16.F10 cells were stained with
hydroethidine (red), and tumor-specific CD8 CTLs were stained with sulfofluoresceindiacetate (green). The 2 cell
populations were then cocultured and subjected to 2-color flow cytometry. The binding of CD8 CTLs and B16.F10
cells is defined as the double positive population in the right upper quadrant. A to C, Cytograms from a
representative experiment of 3 independent experiments. A, Naive B16.F10 cells cocultured with CD8 CTLs. B,
rmIFN-exposed B16.F10 cells cocultured with CD8 CTLs. C, rmIFN-exposed B16.F10 cells cocultured with CTLs
and anti-MHC class I MAb. D, Summary data from 3 separate experiments performed. The % binding is defined as:
Binding (%)  (no. of green-red double positive cells)/(no. of green positive cells)  100. Each bar represents the
mean  SEM.
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hanced on B16.F10 cells and whether this up-regulation
would result in (1) more efficient tumor-specific CTL gen-
eration in tumor-bearing mice (afferent limb) and (2) more
efficient tumor cell–induced binding and activation of tu-
mor-specific CTLs (efferent limb). The data show that MHC
class I expression by B16.F10 cells is readily enhanced by
exposure to the murine cytokine, rmIFN, in vitro and in
vivo, and that this up-regulation results in more efficient
binding of tumor-specific CTLs to B16.F10 cells. Further-
more, a single dose of rmIFN enhances the generation of
CTLs by tumor-bearing mice (afferent limb) and augments
the antitumor effect and cure rate observed with an estab-
lished active immunotherapy strategy (AdCD40L). Finally,
B16.F10 cells that have been exposed to rmIFN are more
potent activators of CTLs than tumor cells that have been
exposed to this cytokine.
Enhancement of the Afferent Limb of the Antitumor
Immune Response by a Single Dose of rmIFN
The afferent limb of the antitumor immune response in-
volves presentation of tumor-associated antigens to naive
CD8 T lymphocytes, a process that requires MHC class I
expression by tumor cells.1-3 With the addition of costimu-
Figure 5. In vivo administration of a single dose of rmIFN to
tumor-bearing mice enhances tumor-specific CTL generation in-
duced by AdCD40L. CTLs were harvested from tumor-bearing
mice and evaluated for IFN release (activation) using the ELIS-
POT assay as described in Materials and Methods. Each bar
represents the mean number of spots  SEM from a total of 3
wells for each group. Target cells for this experiment consisted
of only untreated B16.F10 tumor cells.
Figure 4. Pretreatment of B16.F10 cells with rmIFN results in more efficient stimulation of tumor-specific CTLs in
vitro. CTLs were harvested from mice and evaluated for IFN release (activation) in the ELISPOT assay as
described in Materials and Methods. Each bar represents the mean number of spots  SEM from a total of 3 wells
from each group. A, Splenocytes from AdCD40L-treated, tumor-bearing mice. B, Splenocytes from tumor-bearing
mice receiving no treatment. C, Splenocytes from AdNull-treated, tumor-bearing mice. D, Splenocytes from
untreated, tumor-free mice. *No spots detected.
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lation, these T cells are then able to differentiate into tumor-
specific CTLs, proliferate, and circulate throughout the
body. In this regard, AdCD40L is an adenovirus gene trans-
fer vector encoding the murine CD40 ligand cDNA and has
been demonstrated to augment the afferent limb of the
antitumor immune response by generating tumor-specific
CTLs when administered intratumorally in mice, resulting
in regression of established tumors.11 Tumor regression and
cure rates are limited, however, when this vector is used to
treat murine tumors that express little or no MHC class I
(eg, B16.F10).11 As a strategy to augment the antitumor
effect of AdCD40L when used to treat MHC class I–defi-
cient tumors, we sought to up-regulate MHC class I expres-
sion on established tumors in vivo using rmIFN, a cytokine
known to modulate MHC class I expression by many tumor
cell types in vitro.8,10,26 Interestingly, only a single dose of
systemic rmIFN was necessary to markedly enhance MHC
class I expression by established B16.F10 tumors in vivo.
Furthermore, the data show that the same dose of rmIFN
had virtually no antitumor effect or CTL-generating ability
on its own in this model. When combined with AdCD40L,
however, rmIFN induced pronounced augmentation of
both the antitumor response and cure rate, as well as CTL
generation induced by this vector. The observation that
intratumoral injection of a class I antibody partially abro-
gated the CTL response in this model suggests that the class
I–modulating properties of IFN are responsible for its
synergistic effects. However, this direct cause-and-effect
relationship cannot be stated with certainty as CD40 ligation
itself has been shown to up-regulate class I expression on
some carcinomas.27 Complete abrogation was not observed
in this experiment most likely because the antibody was
administered only on 3 days, allowing the synergistic anti-
tumor effects of IFN to emerge by the time the spleens
were harvested for the ELISPOT assay (7 days posttreat-
ment). Only 3 doses of antibody were used for these exper-
iments for 2 reasons. First is the high cost of the antibody.
Second, in the tumor size experiment (Figure 7, A), it was
desired to temporarily block class I, show a significant
difference in tumor size, then withdraw the antibody to
demonstrate dissipation of this difference.
Enhancement of the Efferent Limb of the Antitumor
Immune Response by a Single Subtherapeutic Dose of
rmIFN
The efferent limb of the antitumor immune response is
invoked when antigen-specific, differentiated CTLs reen-
counter tumor cells expressing the original tumor-associated
antigens. The CTLs then bind to the tumor cell via interac-
tion between MHC class I and the CD8 T-cell receptor,
resulting in activation of the CTL, cytokine release, and
initiation of the apoptotic cascade in the bound tumor
cell.1-3 Given the vital role of MHC class I in CTL binding
and activation in the efferent limb, we sought to determine
whether prior exposure of target tumor cells to rmIFN
would make these processes more efficient based on the
ability of this cytokine to up-regulate MHC class I expres-
sion. The present study suggests that this is true and is
supported by the following observations. First, although
CTLs from AdCD40L-treated mice bind target B16.F10
cells in vitro, this binding is significantly more pronounced
if the tumor cells are pretreated with rmIFN. Second, this
Figure 6. A single dose of rmIFN enhances the antitumor effect and cure rate obtained with intratumoral injection
of AdCD40L. Twelve days after B16.F10 flank tumor initiation, C57BL/6 mice were randomized to 6 groups: AdCD40L
plus IP rmIFN (n  6); AdCD40L alone (n  6); AdNull plus IP rmIFN (n  6); AdNull alone (n  5); IP rmIFN
alone (n  5); or PBS (n  5). All vectors were administered intratumorally (5  1010 particle units/100 L of PBS),
and mIFN (5000 U) was administered concomitantly with the adenovirus vectors. The tumor area was assessed
at 2- to 3-day intervals with microcalipers. The data points represent the mean tumor area  SEM. The mice were
killed when the largest tumor diameter reached 15 mm. A, Tumor area. B, Survival. The arrows indicate the day
of treatment.
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enhanced binding induced by rmIFN is abrogated by the
addition of an anti-MHC class I MAb to the reaction con-
ditions. Finally, the proportion of tumor-specific CTLs that
are activated by exposure to B16.F10 tumor cells in the
ELISPOT assay is markedly increased by pretreatment of
the tumor cells with rmIFN, confirming that the up-regu-
lated MHC class I is indeed a functional receptor.
Clinical Implications of MHC Class I Expression
Modulation
Given the relative lack of significant antitumor responses in
clinical immunotherapy trials25,28 and the common obser-
vation that human tumors seem to down-regulate MHC
class I expression to evade the immune response, enhance-
ment of MHC class I expression to augment CTL generation
represents a valid approach to enhance the antitumor im-
mune response induced by clinical immunotherapeutic strat-
egies. IFN is a reasonable agent to investigate in this
regard because (1) its ability to enhance MHC class I
expression in multiple tumor types in vitro is reasonably
well characterized8,10,26; (2) the data from the present study
suggest that it may be used in this capacity at a low,
subtherapeutic, nontoxic dose; and (3) its toxicity profile
has already been elucidated in humans.29 Despite these
advantages, some tumor cell lines are unresponsive to the
class I–modulating properties of IFN.8 As a result, further
investigation regarding both the mechanism of class I up-
regulation, as well as other modulating agents, is warranted.
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Discussion
Dr Dao D. Nguyen (Bethesda, Md). How toxic is IFN injec-
tion to animals?
Dr Merritt. We gave a single intraperitoneal injection at the
time that we gave an intratumoral injection of either AdCD40
ligand or the control vector.
Dr Nguyen. For future application, how do you envision using
this strategy in human immunotherapy? I guess, and Dr Korst can
correct me, if you’re planning to develop this treatment for lung
cancer, for example, which is very poor at expressing MHC class
I, how do you plan to up-regulate class I expression?
Dr Merritt. Well, in terms of toxicity, it’s already been worked
out for IFN in previous studies treating human renal cell carci-
noma. We would essentially give an intratumoral injection of the
AdCD40 ligand and then give intravenous IFN at the time of
therapy.
Dr Nguyen. Are you planning to use all the pharmacologics
that might up-regulate for MHC class I? We have done that before
using a drug like decitabine, which is a demethylating agent, and
there is increase in expression of class I in the culture lung cancer
cell lines. Do you have any plan of using all the strategies besides
IFN used to up-regulate the MHC class I expression?
Dr Merritt. No. Initially we would start with giving intrave-
nous IFN in combination with our adenoviral gene transfer vector
to see if we could get efficacy. That would be the initial experi-
ment.
Dr Richard J. Battafarano (St Louis, Mo). It’s pretty clear
that you need class I expression for your CTLs to lyse the tumor
cells. But really, what your data shows is that you need class I
expression to actually generate the immune response, I assume
through your dendritic cells, because the CD40 ligand would
enhance the dendritic cells. Why do you think class I expression is
so important on the tumors at the time that you’re generating the
immune response? It’s clear why it would be important at the time
you’re trying to lyse the tumor cells. Why do you think class I
expression is important then?
Dr Merritt. In previous studies where the AdCD40 ligand was
used as a monotherapy, there was actually an antitumor response
that was demonstrated in mirroring cell lines that were immuno-
genic and that expressed MHC class I. And in the murine cancer
lines that did not express class I, there was a less effective
antitumor effect. We think that the IFN is augmenting the MHC
class I up-regulated on the immunogenic cell lines, therefore
making these cells more susceptible to CTL-mediated cell lysis.
Dr Battafarano. But do you think that there is something else
being up-regulated, that there is some other tumor antigen that
might be being up-regulated in there, and that’s really what the
dendritic cells are processing?
Dr Merritt. Do you mean in terms of costimulatory molecules?
It would be hard for us to ascertain that based on just this study
alone. But it is a possibility.
Dr Robert J. Korst (New York, NY). The Achilles’ heel of this
strategy is that it is hard to predict which tumors will be refractory
to IFN gamma, and which will upregulate class I with other agents,
including retinoids. Also, the exact mechanism behind this upregu-
lation is unclear.
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